Stephens initiated coverage on Pacific Biosciences of California Inc (NASDAQ: PACB), noting a solid management team, the market opportunity of long-read, and refraining from taking over the short-read market.
PACB offers next-generation sequencing (NGS) products and solutions. The analyst views it as a large, attractive end market with a significant growth runway.
The analyst notes Revio, its next-generation long-read sequencer as a disruptive technology.
Revio is driving broader adoption of long-read within existing applications while expanding the use case for long-read sequencing in new applications.
The analysts Mason Carrico and Jacob Krahenbuhl have initiated with an Overweight rating and a